RXPA380 | CAS#564479-79-4

MedKoo Cat#: 555337 | Name: RXPA380

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RXPA380 is a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.

Chemical Structure

RXPA380

CAS#564479-79-4

Theoretical Analysis

MedKoo Cat#: 555337

Name: RXPA380

CAS#: 564479-79-4

Chemical Formula: C33H36N3O7P

Exact Mass: 617.2291

Molecular Weight: 617.64

Elemental Analysis: C, 64.17; H, 5.88; N, 6.80; O, 18.13; P, 5.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

RXPA380; RXPA-380; RXPA 380; Cbz-PhePsi[PO(2)CH]Pro-Trp-OH.

IUPAC/Chemical Name

N-[[2-[Hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-L-tryptophan

InChi Key

IMPJIKIXNAGRCR-SFOGZRFBSA-N

InChi Code

InChI=1S/C33H36N3O7P/c37-31(35-28(32(38)39)19-24-20-34-27-16-8-7-14-25(24)27)26-15-9-17-29(26)44(41,42)30(18-22-10-3-1-4-11-22)36-33(40)43-21-23-12-5-2-6-13-23/h1-8,10-14,16,20,26,28-30,34H,9,15,17-19,21H2,(H,35,37)(H,36,40)(H,38,39)(H,41,42)/t26?,28-,29?,30+/m0/s1

SMILES Code

O=C(O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C3C(P([C@@H](NC(OCC4=CC=CC=C4)=O)CC5=CC=CC=C5)(O)=O)CCC3)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 617.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Anthony CS, Masuyer G, Sturrock ED, Acharya KR. Structure based drug design of angiotensin-I converting enzyme inhibitors. Curr Med Chem. 2012;19(6):845-55. Review. PubMed PMID: 22214449. 2: Akif M, Georgiadis D, Mahajan A, Dive V, Sturrock ED, Isaac RE, Acharya KR. High-resolution crystal structures of Drosophila melanogaster angiotensin-converting enzyme in complex with novel inhibitors and antihypertensive drugs. J Mol Biol. 2010 Jul 16;400(3):502-17. doi: 10.1016/j.jmb.2010.05.024. Epub 2010 May 19. PubMed PMID: 20488190. 3: Kröger WL, Douglas RG, O'Neill HG, Dive V, Sturrock ED. Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme. Biochemistry. 2009 Sep 8;48(35):8405-12. doi: 10.1021/bi9011226. PubMed PMID: 19658433. 4: van Esch JH, van Gool JM, de Bruin RJ, Payne JR, Montgomery HE, Hectors M, Deinum J, Dive V, Jan Danser AH. Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype. J Hypertens. 2008 Apr;26(4):706-13. doi: 10.1097/HJH.0b013e3282f465d2. PubMed PMID: 18327080. 5: Corradi HR, Chitapi I, Sewell BT, Georgiadis D, Dive V, Sturrock ED, Acharya KR. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry. 2007 May 8;46(18):5473-8. Epub 2007 Apr 18. PubMed PMID: 17439247. 6: Jullien ND, Cuniasse P, Georgiadis D, Yiotakis A, Dive V. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme. FEBS J. 2006 Apr;273(8):1772-81. PubMed PMID: 16623712. 7: Bingham RJ, Dive V, Phillips SE, Shirras AD, Isaac RE. Structural diversity of angiotensin-converting enzyme. FEBS J. 2006 Jan;273(2):362-73. PubMed PMID: 16403023. 8: van Esch JH, Tom B, Dive V, Batenburg WW, Georgiadis D, Yiotakis A, van Gool JM, de Bruijn RJ, de Vries R, Danser AH. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension. 2005 Jan;45(1):120-5. Epub 2004 Dec 6. PubMed PMID: 15583077. 9: Georgiadis D, Cuniasse P, Cotton J, Yiotakis A, Dive V. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. Biochemistry. 2004 Jun 29;43(25):8048-54. PubMed PMID: 15209500. 10: Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res. 2003 Jul 25;93(2):148-54. Epub 2003 Jun 12. PubMed PMID: 12805239.